BioTime to Present Additional Data at Upcoming ARVO
Retinal tissue regeneration presentation added
OpRegen® presentation scheduled for May 8
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2017--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that an abstract related to the Company’s
retinal tissue implant has been accepted for a paper presentation at the Annual
Meeting of the Association for Research in Vision and Ophthalmology
(ARVO) in Baltimore, Maryland, May 7-11.
“This presentation is in addition to the poster presentation based on
data from our Phase I/IIa clinical trial of OpRegen in the advanced form
of dry-AMD. Ophthalmology is one of BioTime’s core areas of near-term
strategic focus. We are leveraging our expertise in regenerative
ophthalmology to build a strong pipeline of therapeutics to address a
large number of degenerative diseases of the eye,” said Adi Mohanty,
Co-Chief Executive Officer of BioTime.
OpRegen has received Fast Track designation from the FDA for
treatment of the advanced form of dry-AMD. Details of the trial and
about a patient’s eligibility are available at https://clinicaltrials.gov/
with the following Identifier: NCT02286089 (dry-AMD).
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005408/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
Gotham Communications, LLC
Bill Douglass, 646-504-0890